SPOTLIGHT -
Environment, lifestyle play role in AMD disease development
Research shows how life stressors—such as obesity—reprogram immune system cells and make them destructive to the eye as it ages.
First patient dosed in phase 1 study of IBI324 for DME
IBI324 is a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.
LIGHTSITE III trial data shows vision improvement in intermediate dry AMD
Trial results demonstrated statistically significant improvement in the prespecified primary endpoint in BCVA at 13 months in the PBM treatment group over the sham-treatment group.
Research to Prevent Blindness, Aerie partner on glaucoma research grant
Research to Prevent Blindness will launch the RPB/David L. Epstein Career Advancement Award in Glaucoma Research, sponsored by Aerie Pharmaceuticals.
Orbis International celebrates 40 years of innovation
The nonprofit has continually reached for new heights in the fight against avoidable blindness.
How to manage early cataract surgery complications
Review treatment options for both early and late complications of cataract surgery.
Eye drops for presbyopia treatment receive FDA approval
VUITY, developed by Allergan, is the first and only FDA-approved eye drop to treat presbyopia
Genentech’s new treatment for wet AMD receives FDA approval
Susvimo's new therapeutic approach for wet AMD may help patients maintain their vision with as few as 2 treatments per year
